


This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of the Claims:**

1-3. (canceled)

4. (withdrawn) A compound of the formula (II):



(II)

wherein

X is  $-(CH_2)_m-$ ,  $-O-$ ,  $-S(O)_n-$ ,  $-N(R_5)-$ ,  $-CH=CH-$ , or  $-CH_2-CH=CH-$ ;

m is 0, 1, 2 or 3;

n is 0, 1 or 2;

$R_1-R_4$  are the same or different and are each selected from H, lower alkyl,  $-OH$ , and  $CH(R_6)-CONR_7R_8$ ; or any of  $R_1-R_4$  can be taken together to form a 3-7 member

carbocyclic or heterocyclic ring;

$R_5$  is H, lower alkyl, or  $-OH$ ;

$R_6$ ,  $R_7$  and  $R_8$  are each independently H or lower alkyl; and

ring A, together with the carbon atoms to which it is attached is selected from:

a) a 6-membered carbocyclic ring in which from 1 to 3 carbon atoms may be replaced by hetero atoms selected from oxygen, nitrogen and sulfur; and


b) a 5-membered carbocyclic ring in which either:

i) one carbon atom may be replaced with an oxygen, nitrogen, or sulfur atom;

ii) two carbon atoms may be replaced with a sulfur and a nitrogen atom, an oxygen and a nitrogen atom, or two nitrogen atoms; or  
iii) three carbon atoms may be replaced with three nitrogen atoms, one oxygen and two nitrogen atoms, or one sulfur and two nitrogen atoms; and the stereoisomeric forms, mixtures of stereoisomeric forms, or pharmaceutically acceptable salt and ester forms thereof.

5-16. (canceled)

17. (original) A compound of formula (V):



(V)

wherein:

Ar<sub>1</sub> and Ar<sub>2</sub> are each independently selected from C<sub>6</sub>-C<sub>10</sub> aryl or heteroaryl; wherein each of Ar<sub>1</sub> or Ar<sub>2</sub> may be independently optionally substituted with 1-3 substituents independently selected from:

- a) H, C<sub>6</sub>-C<sub>10</sub> aryl, heteroaryl, F, Cl, Br, I, -CN, -CF<sub>3</sub>, -NO<sub>2</sub>, -OH, -OR<sub>7</sub>, -O(CH<sub>2</sub>)<sub>p</sub>NR<sub>9</sub>R<sub>10</sub>, -OC(=O)R<sub>7</sub>, -OC(=O)NR<sub>9</sub>R<sub>10</sub>, -O(CH<sub>2</sub>)<sub>p</sub>OR<sub>8</sub>, -CH<sub>2</sub>OR<sub>8</sub>, -NR<sub>9</sub>R<sub>10</sub>, -NR<sub>8</sub>S(=O)<sub>2</sub>R<sub>7</sub>, -NR<sub>8</sub>C(=O)R<sub>7</sub>, or -NR<sub>8</sub>C(=S)R<sub>7</sub>;
- b) -CH<sub>2</sub>OR<sub>11</sub>;
- c) -NR<sub>8</sub>C(=O)NR<sub>9</sub>R<sub>10</sub>, -NR<sub>8</sub>C(=S)NR<sub>9</sub>R<sub>10</sub>, -CO<sub>2</sub>R<sub>12</sub>, -C(=O)R<sub>13</sub>, -C(=O)NR<sub>9</sub>R<sub>10</sub>, -C(=S)NR<sub>9</sub>R<sub>10</sub>, -CH=NOR<sub>12</sub>, -CH=NR<sub>7</sub>, -(CH<sub>2</sub>)<sub>p</sub>NR<sub>9</sub>R<sub>10</sub>, -(CH<sub>2</sub>)<sub>p</sub>NHR<sub>11</sub>, -CH=NNR<sub>12</sub>R<sub>12A</sub>, -C(=NR<sub>8</sub>)NR<sub>8A</sub>R<sub>8B</sub> -NR<sub>8</sub>C(=NH)R<sub>8A</sub>, -NR<sub>8</sub>C(=NH)NR<sub>8A</sub>R<sub>8B</sub>,
- d) -S(O)<sub>y</sub>R<sub>7</sub>, -(CH<sub>2</sub>)<sub>p</sub>S(O)<sub>y</sub>R<sub>7</sub>, -CH<sub>2</sub>S(O)<sub>y</sub>R<sub>7</sub>; and

or

e)  $C_1\text{-}C_8$  alkyl,  $C_2\text{-}C_8$  alkenyl, or  $C_2\text{-}C_8$  alkynyl, where:

- 1) each alkyl, alkenyl, or alkynyl group is unsubstituted; or
- 2) each alkyl, alkenyl or alkynyl group is independently substituted with 1 to 3 groups independently selected from  $C_6\text{-}C_{10}$  aryl, heteroaryl, F, Cl, Br, I,  $CF_3$ , -CN,  $-\text{NO}_2$ ,  $-\text{OH}$ ,  $-\text{OR}_7$ ,  $-\text{CH}_2\text{OR}_8$ ,  $-\text{NR}_9\text{R}_{10}$ ,  $-\text{O}(\text{CH}_2)_p\text{OH}$ ,  $-\text{S}(\text{CH}_2)_p\text{OH}$ ,  $-\text{X}_1(\text{CH}_2)_p\text{OR}_7$ ,  $\text{X}_1(\text{CH}_2)_p\text{NR}_9\text{R}_{10}$ ,  $-\text{X}_1(\text{CH}_2)_p\text{C}(=\text{O})\text{NR}_9\text{R}_{10}$ ,  $-\text{X}_1(\text{CH}_2)_p\text{C}(=\text{S})\text{NR}_9\text{R}_{10}$ ,  $-\text{X}_1(\text{CH}_2)_p\text{OC}(=\text{O})\text{NR}_9\text{R}_{10}$ ,  $-\text{X}_1(\text{CH}_2)_p\text{CO}_2\text{R}_8$ ,  $-\text{X}_1(\text{CH}_2)_p\text{S(O)}_y\text{R}_7$ ,  $-\text{X}_1(\text{CH}_2)_p\text{NR}_8\text{C}(=\text{O})\text{NR}_9\text{R}_{10}$ ,  $-\text{C}(=\text{O})\text{R}_{13}$ ,  $-\text{CO}_2\text{R}_{12}$ ,  $-\text{OC}(=\text{O})\text{R}_7$ ,  $-\text{C}(=\text{O})\text{NR}_9\text{R}_{10}$ ,  $-\text{OC}(=\text{O})\text{NR}_{12}\text{R}_{12A}$ , O-tetrahydropyranyl,  $-\text{C}(=\text{S})\text{NR}_9\text{R}_{10}$ ,  $-\text{CH}=\text{NNR}_{12}\text{R}_{12A}$ ,  $-\text{CH}=\text{NOR}_{12}$ ,  $-\text{CH}=\text{NR}_7$ ,  $-\text{CH}=\text{NNHCH}(\text{N}=\text{NH})\text{NH}_2$ ,  $-\text{NR}_8\text{CO}_2\text{R}_7$ ,  $-\text{NR}_8\text{C}(=\text{O})\text{NR}_9\text{R}_{10}$ ,  $-\text{NR}_8\text{C}(=\text{S})\text{NR}_9\text{R}_{10}$ ,  $-\text{NHC}(=\text{NH})\text{NH}_2$ ,  $-\text{NR}_8\text{C}(=\text{O})\text{R}_7$ ,  $-\text{NR}_8\text{C}(=\text{S})\text{R}_7$ ,  $-\text{NR}_8\text{S}(=\text{O})_2\text{R}_7$ ,  $-\text{S(O)}_y\text{R}_7$ ,  $-\text{S}(=\text{O})_2\text{NR}_{12}\text{R}_{12A}$ ,  $\text{P}(=\text{O})(\text{OR}_8)_2$ ,  $-\text{OR}_{11}$ , and a  $C_5\text{-}C_7$  monosaccharide where each hydroxyl group of the monosaccharide is independently either unsubstituted or is replaced by H,  $C_1\text{-}C_4$  alkyl,  $C_1\text{-}C_4$  alkoxy, or  $-\text{O-C}(=\text{O})\text{R}_7$ ;

$\text{X}_1$  is  $-\text{O-}$ ,  $-\text{S-}$ ,  $-\text{N}(\text{R}_8)\text{-}$ ;

$\text{J}$  is  $C_2\text{-}C_4$  alkylene or  $\text{Q-CO-}$ ;

$\text{Q}$  is  $C_1\text{-}C_3$  alkylene;

$\text{R}_{2A}$  is H,  $C_1\text{-}C_6$  alkyl, aryl or heteroaryl;

$\text{R}_{4A}$  is H,  $C_1\text{-}C_6$  alkyl, aryl or heteroaryl;

$\text{R}_7$  is  $C_1\text{-}C_6$  alkyl,  $C_6\text{-}C_{10}$  aryl, or heteroaryl;

$\text{R}_8$ ,  $\text{R}_{8A}$  and  $\text{R}_{8B}$  are each independently H,  $C_1\text{-}C_4$  alkyl, or  $C_6\text{-}C_{10}$  aryl;

$\text{R}_9$  and  $\text{R}_{10}$  are independently selected from H,  $C_1\text{-}C_4$  alkyl, and  $C_6\text{-}C_{10}$  aryl; or  $\text{R}_9$  and

$\text{R}_{10}$  together with the nitrogen to which they are attached, form a 3-7 member heterocyclic ring;

$\text{R}_{11}$  is the residue of an amino acid after the hydroxyl group of the carboxyl group is removed;

$R_{12}$  and  $R_{12A}$  are each independently selected from H, C<sub>1</sub>-C<sub>6</sub> alkyl, cycloalkyl, C<sub>6</sub>-C<sub>10</sub> aryl, and heteroaryl; or  $R_{12}$  and  $R_{12A}$ , together with the nitrogen to which they are attached, form a 5-7 member heterocyclic ring;

$R_{13}$  is H, C<sub>1</sub>-C<sub>6</sub> alkyl, cycloalkyl, C<sub>6</sub>-C<sub>10</sub> aryl, heteroaryl, -C(=O)R<sub>7</sub>, -C(=O)NR<sub>9</sub>R<sub>10</sub>, or -C(=S)NR<sub>9</sub>R<sub>10</sub>;

$p$  is from 1, 2, 3, or 4;

$q$  is 0, 1, or 2;


$t$  is 2, 3, or 4;

$y$  is 0, 1 or 2;

and the stereoisomeric forms, mixtures of stereoisomeric forms, or pharmaceutically acceptable salt and ester forms thereof.

18. (original) The compound of claim 17, wherein Ar<sub>1</sub> and Ar<sub>2</sub> are phenyl and  $q=1$ .


19. (original) The compound of claim 17, wherein  $q$  is 1 and J is Q-CO to form a compound of formula (VI):



(VI)

20-22. (canceled)


23. (currently amended) The compound of claim 19, wherein the compounds are selected in accordance with the following table:



No.	<i>Ar</i> <sub>1</sub>	<i>Ar</i> <sub>2</sub>	<i>R</i> <sub>2A</sub>	<i>Q</i>	<i>R</i> <sub>4A</sub>
VI-1	Phenyl	Phenyl	H	CH <sub>2</sub>	H
VI-2	Phenyl	Phenyl	H	CH <sub>2</sub>	CH <sub>3</sub>
VI-3	Phenyl	Phenyl	H	CH <sub>2</sub>	(CH <sub>2</sub> ) <sub>2</sub> OMe
VI-4	Phenyl	Phenyl	H	CH <sub>2</sub>	(CH <sub>2</sub> ) <sub>2</sub> OH
VI-5	Phenyl	Phenyl	H	CH <sub>2</sub>	( <i>s</i> )-CH(CH <sub>3</sub> )CH <sub>2</sub> OH
VI-6	4-Fluorophenyl	4-Fluorophenyl	H	CH <sub>2</sub>	CH <sub>3</sub>
VI-7	3-Thienyl	3-Thienyl	H	CH <sub>2</sub>	H
VI-8	3-Thienyl	Phenyl	H	CH <sub>2</sub>	H
VI-9	Phenyl	Phenyl	H	(CH <sub>2</sub> ) <sub>2</sub>	H

24-32. (canceled)

33. (withdrawn) A compound of formula (VII):



(VII)

wherein


*X* is a bond, -CH<sub>2</sub>CH<sub>2</sub>-, -O-, -S(O)<sub>y</sub>-, -N(R<sub>8</sub>)-, -CHN(R<sub>8</sub>)-, -CH=CH-, -CH<sub>2</sub>-CH=CH-, C(=O), -C(R<sub>8</sub>)=N-, -N=C(R<sub>8</sub>)-, -C(=O)-N(R<sub>8</sub>)-, or -NR<sub>8</sub>-C(=O)-;

Rings A and B, together with the carbon atoms to which they are attached, are each independently selected from:

- a) a 6-membered aromatic carbocyclic ring in which from 1 to 3 carbon atoms may be replaced by hetero atoms selected from oxygen, nitrogen and sulfur; and
- b) a 5-membered aromatic carbocyclic ring in which either:
  - i) one carbon atom is replaced with an oxygen, nitrogen, or sulfur atom;
  - ii) two carbon atoms are replaced with a sulfur and a nitrogen atom, an oxygen and a nitrogen atom, or two nitrogen atoms; or
  - iii) three carbon atoms are replaced with three nitrogen atoms, one oxygen and two nitrogen atoms, or one sulfur and two nitrogen atoms;

wherein Ring A and Ring B may each independently be substituted with 1-3 substituents selected from:

- a) H, C<sub>6</sub>-C<sub>10</sub> aryl, heteroaryl, F, Cl, Br, I, -CN, -CF<sub>3</sub>, -NO<sub>2</sub>, -OH, -OR<sub>7</sub>, -O(CH<sub>2</sub>)<sub>p</sub>NR<sub>9</sub>R<sub>10</sub>, -OC(=O)R<sub>7</sub>, -OC(=O)NR<sub>9</sub>R<sub>10</sub>, -O(CH<sub>2</sub>)<sub>p</sub>OR<sub>8</sub>, -CH<sub>2</sub>OR<sub>8</sub>, -NR<sub>9</sub>R<sub>10</sub>, -NR<sub>8</sub>S(=O)<sub>2</sub>R<sub>7</sub>, -NR<sub>8</sub>C(=O)R<sub>7</sub>, or -NR<sub>8</sub>C(=S)R<sub>7</sub>;
- b) -CH<sub>2</sub>OR<sub>11</sub>;
- c) -NR<sub>8</sub>C(=O)NR<sub>9</sub>R<sub>10</sub>, -NR<sub>8</sub>C(=S)NR<sub>9</sub>R<sub>10</sub>, -CO<sub>2</sub>R<sub>12</sub>, -C(=O)R<sub>13</sub>, -C(=O)NR<sub>9</sub>R<sub>10</sub>, -C(=S)NR<sub>9</sub>R<sub>10</sub>, -CH=NOR<sub>12</sub>, -CH=NR<sub>7</sub>, -(CH<sub>2</sub>)<sub>p</sub>NR<sub>9</sub>R<sub>10</sub>, -(CH<sub>2</sub>)<sub>p</sub>NHR<sub>11</sub>, -CH=NNR<sub>12</sub>R<sub>12A</sub>, -C(=NR<sub>8</sub>)NR<sub>8A</sub>R<sub>8B</sub> -NR<sub>8</sub>C(=NH)R<sub>8A</sub>, -



- NR<sub>8</sub>C(=NH)NR<sub>8A</sub>R<sub>8B</sub>,
- d) -S(O)<sub>y</sub>R<sub>7</sub>, -(CH<sub>2</sub>)<sub>p</sub>S(O)<sub>y</sub>R<sub>7</sub>, -CH<sub>2</sub>S(O)<sub>y</sub>R<sub>7</sub>; and
- e) C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, or C<sub>2</sub>-C<sub>8</sub> alkynyl, where:
  - 1) each alkyl, alkenyl, or alkynyl group is unsubstituted; or
  - 2) each alkyl, alkenyl or alkynyl group is independently substituted with 1 to 3 groups independently selected from C<sub>6</sub>-C<sub>10</sub> aryl, heteroaryl, F, Cl, Br, I, CF<sub>3</sub>, -CN, -NO<sub>2</sub>, -OH, -OR<sub>7</sub>, -CH<sub>2</sub>OR<sub>8</sub>, -NR<sub>9</sub>R<sub>10</sub>, -O-(CH<sub>2</sub>)<sub>p</sub>-OH, -S-(CH<sub>2</sub>)<sub>p</sub>-OH, -X<sub>1</sub>(CH<sub>2</sub>)<sub>p</sub>OR<sub>7</sub>, X<sub>1</sub>(CH<sub>2</sub>)<sub>p</sub>NR<sub>9</sub>R<sub>10</sub>, -X<sub>1</sub>(CH<sub>2</sub>)<sub>p</sub>C(=O)NR<sub>9</sub>R<sub>10</sub>, -

$X_1(CH_2)_pC(=S)NR_9R_{10}$ ,  $-X_1(CH_2)_pOC(=O)NR_9R_{10}$ , -  
 $X_1(CH_2)_pCO_2R_8$ ,  $-X_1(CH_2)_pS(O)_yR_7$ ,  $-X_1(CH_2)_pNR_8C(=O)NR_9R_{10}$ , -  
 $-C(=O)R_{13}$ ,  $-CO_2R_{12}$ ,  $-OC(=O)R_7$ ,  $-C(=O)NR_9R_{10}$ , -  
 $OC(=O)NR_{12}R_{12A}$ , O-tetrahydropyranyl,  $-C(=S)NR_9R_{10}$ , -  
 $CH=NNR_{12}R_{12A}$ ,  $-CH=NOR_{12}$ ,  $-CH=NR_7$ , -  
 $CH=NNHCH(N=NH)NH_2$ ,  $-NR_8CO_2R_7$ ,  $-NR_8C(=O)NR_9R_{10}$ , -  
 $NR_8C(=S)NR_9R_{10}$ ,  $-NHC(=NH)NH_2$ ,  $-NR_8C(=O)R_7$ , -  
 $NR_8C(=S)R_7$ ,  $-NR_8S(=O)_2R_7$ ,  $-S(O)_yR_7$ ,  $-S(=O)_2NR_{12}R_{12A}$ , -  
 $P(=O)(OR_8)_2$ ,  $-OR_{11}$ , and a C<sub>5</sub>-C<sub>7</sub> monosaccharide where each  
hydroxyl group of the monosaccharide is independently either  
unsubstituted or is replaced by H, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, or -  
 $O-C(=O)R_7$ ;

J is C<sub>2</sub>-C<sub>4</sub> alkylene or Q-CO-;

Q is C<sub>1</sub>-C<sub>3</sub> alkylene;

R<sub>2A</sub> is H, C<sub>1</sub>-C<sub>6</sub> alkyl, aryl or heteroaryl;

R<sub>4A</sub> is H, C<sub>1</sub>-C<sub>6</sub> alkyl, aryl or heteroaryl;

R<sub>7</sub> is C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>6</sub>-C<sub>10</sub> aryl, or heteroaryl;

R<sub>8</sub>, R<sub>8A</sub> and R<sub>8B</sub> are each independently H, C<sub>1</sub>-C<sub>4</sub> alkyl, or C<sub>6</sub>-C<sub>10</sub> aryl;

R<sub>9</sub> and R<sub>10</sub> are independently selected from H, C<sub>1</sub>-C<sub>4</sub> alkyl, and C<sub>6</sub>-C<sub>10</sub> aryl; or R<sub>9</sub> and  
R<sub>10</sub> together with the nitrogen to which they are attached, form a 3-7 member  
heterocyclic ring;

R<sub>11</sub> is the residue of an amino acid after the hydroxyl group of the carboxyl group is  
removed;

R<sub>12</sub> and R<sub>12A</sub> are each independently selected from H, C<sub>1</sub>-C<sub>6</sub> alkyl, cycloalkyl, C<sub>6</sub>-C<sub>10</sub>  
aryl, and heteroaryl; or R<sub>12</sub> and R<sub>12A</sub>, together with the nitrogen to which they are  
attached, form a 5-7 member heterocyclic ring;

R<sub>13</sub> is H, C<sub>1</sub>-C<sub>6</sub> alkyl, cycloalkyl, C<sub>6</sub>-C<sub>10</sub> aryl, heteroaryl,  $-C(=O)R_7$ ,  $-C(=O)NR_9R_{10}$ , or -  
 $C(=S)NR_9R_{10}$ ;

X<sub>1</sub> is -O-, -S-, -N(R<sub>8</sub>)-;

p is from 1 to 4;

q is 0, 1, or 2;


t is 2, 3, or 4;

y is 0, 1 or 2;

and the stereoisomeric forms, mixtures of stereoisomeric forms, or pharmaceutically acceptable salt and ester forms thereof.


34. (withdrawn) The compound of claim 33, wherein rings A and B are benzo; X is a bond or -O- and q=1.

35. (withdrawn) The compound of claim 34, having the formula (VII-1):



(VII-1)

36. (withdrawn) The compound of claim 33, wherein q is 1; and J is Q-CO- to form a compound of formula (VIII):




(VIII)

37. (withdrawn) The compound of claim 36, wherein rings A and B are benzo; and X is a bond or -O-.

38. (canceled)

39. (withdrawn) The compound of claim 36, wherein the compounds are selected in accordance with the following table:



(VIII)

No.	A	B	X	R <sub>2A</sub>	Q	R <sub>4A</sub>
VIII-1	Benzo	Benzo	bond	H	CH <sub>2</sub>	H
VIII-2	Benzo	Benzo	bond	H	CH <sub>2</sub>	Me
VIII-3	Benzo	Benzo	bond	H	CH <sub>2</sub>	(CH <sub>2</sub> ) <sub>2</sub> OMe
VIII-4	Benzo	Benzo	bond	H	CH <sub>2</sub>	(CH <sub>2</sub> ) <sub>2</sub> OH
VIII-5	Benzo	Benzo	bond	H	CH <sub>2</sub>	CH(CH <sub>3</sub> )CH <sub>2</sub> OH
VIII-6	Benzo	Benzo	bond	H	CH <sub>2</sub>	OH
VIII-7	Benzo	Benzo	bond	H	CH <sub>2</sub>	CH <sub>2</sub> -(4-methoxyphenyl)
VIII-8	Benzo	Benzo	bond	H	CH <sub>2</sub>	Ph
VIII-9	Benzo	Benzo	bond	H	(CH <sub>2</sub> ) <sub>2</sub>	H

40. (withdrawn) The compound of claim 4, wherein ring A is selected from thiophene, isothiazole, phenyl, oxazole, isoxazole, thiazole, and imidazole.

41. (canceled)

42. (currently amended) ~~The method of claim 41, wherein the compound is administered~~ ~~A method of treating diseases or disorders in a subject in need thereof~~ comprising administering a therapeutically effective amount of a compound of claim 17 to the subject for the treatment of sleepiness, tiredness, Parkinson's disease, cerebral ischemia, stroke, sleep apneas, eating disorders, attention deficit hyperactivity disorder, cognitive dysfunction or fatigue; or for the promotion of wakefulness, stimulation of appetite, or stimulation of weight gain.

43. (currently amended) ~~The method of claim 41, wherein the compound is administered A method of treating diseases or disorders in a subject in need thereof comprising administering a therapeutically effective amount of a compound of claim 17 to the subject~~ for the treatment of disorders associated with hypofunctionality of the cerebral cortex.

44. (previously presented) The method of claim 43, wherein the compound is administered for the treatment of depression, schizophrenia, or chronic fatigue syndrome.

45. (currently amended) A pharmaceutical composition comprising a compound of ~~claims 4, 17 or 33~~ claim 17 in admixture with one or more pharmaceutically acceptable excipients.

46. (withdrawn) The compound of claim 4 wherein ring A is thiophenylene or phenylene.

47. (withdrawn) The compound of claim 46 wherein ring A is phenylene.

48. (withdrawn) The compound of claim 47 wherein X is a bond.

49. (withdrawn) The compound of claim 47 wherein X is -O-.

50. (withdrawn) The compound of claim 47 wherein X is -NCH<sub>3</sub>.

51. (withdrawn) The compound of claim 47 wherein X is -S-.

52. (withdrawn) The compound of claim 4 wherein n is 1.

53. (withdrawn) The compound of claim 4 wherein R<sub>3</sub> and R<sub>4</sub> are taken together with the nitrogen to which they are attached to form a morpholine ring.

54. (previously presented) The compound of claim 17 wherein Ar<sub>1</sub> and Ar<sub>2</sub> are each independently phenyl or thiienyl.

55. (previously presented) The compound of claim 54 wherein Ar<sub>1</sub> and Ar<sub>2</sub> are phenyl.

56. (previously presented) The compound of claim 17 wherein q is 1.

57. (previously presented) The compound of claim 17 wherein J is C<sub>2</sub> alkylene.

58. (previously presented) The compound of claim 17 wherein J is C<sub>3</sub> alkylene.

59. (previously presented) The compound of claim 17 wherein R<sub>2A</sub> is H or C<sub>1</sub>-C<sub>6</sub> alkyl and R<sub>4A</sub> is phenyl, thienyl or pyridyl.


60. (previously presented) The compound of claim 59 wherein R<sub>4A</sub> is phenyl.

61. (previously presented) The compound of claim 17 wherein Ar<sub>1</sub> and Ar<sub>2</sub> are phenyl, q is 1, and J is C<sub>2</sub>-C<sub>3</sub> alkylene.

62. (previously presented) The compound of claim 19 wherein Q is C<sub>1</sub> alkylene.

63. (previously presented) The compound of claim 19 wherein Q is C<sub>2</sub> alkylene.

64. (currently amended) The compound of claim 19 wherein the compound is selected in accordance with the following table:



No.	Ar <sub>1</sub>	Ar <sub>2</sub>	R <sub>2A</sub>	Q	R <sub>4A</sub>
VI-1	Phenyl	Phenyl	H	CH <sub>2</sub>	H
VI-2	Phenyl	Phenyl	H	CH <sub>2</sub>	CH <sub>3</sub>
VI-3	Phenyl	Phenyl	H	CH <sub>2</sub>	(CH <sub>2</sub> ) <sub>2</sub> OMe
VI-4	Phenyl	Phenyl	H	CH <sub>2</sub>	(CH <sub>2</sub> ) <sub>2</sub> OH
VI-5	Phenyl	Phenyl	H	CH <sub>2</sub>	(S)-CH(CH <sub>3</sub> )CH <sub>2</sub> OH
VI-6	4-Fluorophenyl	4-Fluorophenyl	H	CH <sub>2</sub>	CH <sub>3</sub>
VI-7	3-Thienyl	3-Thienyl	H	CH <sub>2</sub>	H
VI-8	3-Thienyl	Phenyl	H	CH <sub>2</sub>	H
VI-9	Phenyl	Phenyl	H	(CH <sub>2</sub> ) <sub>2</sub>	H

65. (withdrawn) The compound of claim 33 wherein rings A and B are each independently selected from phenylene and thienylene.

66. (withdrawn) The compound of claim 65 wherein rings A and B are phenylene.

67. (withdrawn) The compound of claim 33 wherein q is 1.

68. (withdrawn) The compound of claim 33 wherein X is a bond, -O-, or CH<sub>2</sub>CH<sub>2</sub>.

69. (withdrawn) The compound of claim 68 wherein X is a bond.

70. (withdrawn) The compound of claim 33 wherein J is C<sub>2</sub> alkylene.

71. (withdrawn) The compound of claim 33 wherein J is C<sub>3</sub> alkylene.

72. (withdrawn) The compound of claim 33 wherein rings A and B are phenylene, X is a bond, -O-, or  $\text{CH}_2\text{CH}_2$ , q is 1, and J is  $\text{C}_2\text{-C}_3$  alkylene.